GlassScriptPhysician profile
Michelle Snow
NPI 1699317438
$924.55
in general payments reported to CMS, 2019-2025
14 companies · $730 in 2025
The $730 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $195 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.21 | 2024-2025 | Jardiance |
| Boston Scientific Corporation | $149.64 | 2024-2025 | Watchman Flx |
| Daiichi Sankyo INC. | $110.51 | 2024 | Injectafer |
| Amgen INC. | $77.09 | 2024-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $65.91 | 2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $53.80 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $50.48 | 2024-2025 | Opsumit, Uptravi |
| Pfizer INC. | $45.63 | 2025 | |
| Bridgebio Pharma, INC. | $40.71 | 2025 | Attruby |
| Scpharmaceuticals INC. | $39.14 | 2025 | |
| Novo Nordisk INC | $29.63 | 2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $20.03 | 2025 | Verquvo |
| Vertex Pharmaceuticals Incorporated | $16.05 | 2025 | |
| Abiomed | $15.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.